AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced today that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® (also known as rintatolimod) at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center

AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9 million.

AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline

AIM ImmunoTech Inc (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its chief financial officer (CFO).  Effective April 4, 2022, AIM ImmunoTech said, Dickey will become CFO and current CFO Ellen Lintal will transition to serve as a finance and accounting consultant for the company.

AIM ImmunoTech announces appointment of Robert Dickey IV, as its chief financial officer

Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companies Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companies

AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer

AIM ImmunoTech management to participate in webinar Thursday, January 27 th from 2:00 pm - 3:00 pm ET

AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.  The study has been published in the American Association for Cancer Research publication, Clinical Cancer Research under the title, “Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.

AIM ImmunoTech announces positive results from Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer

Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function

AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

AIM ImmunoTech Inc (NYSE:AIM) has announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria. The conference, which ran from December 4-7, 2021, also included research on coronavirus (COVID-19) and respiratory syncytial virus.

AIM ImmunoTech's Ampligen safety data presented at Eighth European Scientific Working Group on Influenza.

OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. The conference also included research on COVID-19 and respiratory syncytial virus.

AIM ImmunoTech's Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.

AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Inc (NYSE:AIM) closed its third quarter with a $53.7 million balance sheet as the company advances Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.  “We are proud of the progress made through the third quarter,” said CEO Thomas Equels in a statement.

AIM ImmunoTech closes 3Q with $53.7M balance sheet

OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update.

AIM ImmunoTech Provides Third Quarter 2021 Business Update

AIM ImmunoTech Inc said it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the US Food and Drug Administration (FDA) for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.  The company said the planned AMP-270 clinical trial of around 250 subjects will be a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen when added to SOC (standard of care) versus SOC alone for subjects with advanced pancreatic carcinoma recently treated with FOLFIRINOX chemotherapy regimen.

AIM ImmunoTech submits IND and Fast Track applications for Phase 2 trial of Ampligen pancreatic cancer therapy

OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company's drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.

AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no severe adverse events" and that the drug was "generally well tolerated". The trial saw 40 healthy subjects receive either Ampligen or a placebo, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms.

AIM ImmunoTech moving forward to develop Ampligen as intranasal coronavirus treatment as it publishes Phase I safety data

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19.

AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expects to submit both an Investigational New Drug application (IND) and a request for Fast Track status with the US Food and Drug Administration (FDA) by no later than October 18.

AIM ImmunoTech finalizes protocol for planned Phase 2 study of Ampligen in patients with pancreatic cancer

Finalizes and reports Phase 2 study protocol

AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.

AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial (HCT) with hVIVO for a Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).

AIM ImmunoTech inks clinical trial agreement for a Phase 2a Human Challenge Trial of Ampligen as an intranasal prophylaxis against respiratory viruses

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter

AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19.

News for AIM ImmunoTech Inc Stock (AIM)